Literature DB >> 27881676

Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages.

Brian J Girard1, Todd P Knutson1, Bethanie Kuker1, Laura McDowell1, Kathryn L Schwertfeger1,2, Julie H Ostrander3,4.   

Abstract

Cytoplasmic localization of proline, glutamic acid, leucine-rich protein 1 (PELP1) is observed in ∼40% of women with invasive breast cancer. In mouse models, PELP1 overexpression in the mammary gland leads to premalignant lesions and eventually mammary tumors. In preliminary clinical studies, cytoplasmic localization of PELP1 was seen in 36% of women at high risk of developing breast cancer. Here, we investigated whether cytoplasmic PELP1 signaling promotes breast cancer initiation in models of immortalized human mammary epithelial cells (HMECs). Global gene expression analysis was performed on HMEC lines expressing vector control, PELP1-wt, or mutant PELP1 in which the nuclear localization sequence was altered, resulting in cytoplasmic localization of PELP1 (PELP1-cyto). Global gene expression analysis identified that PELP1-cyto expression in HMECs induced NF-κB signaling pathways. Western blotting analysis of PELP1-cyto HMECs showed up-regulation of inhibitor of κB kinase ϵ (IKKϵ) and increased phosphorylation of the NF-κB subunit RelB. To determine whether secreted factors produced by PELP1-cyto HMECs promote macrophage activation, THP-1 macrophages were treated with HMEC-conditioned medium (CM). PELP1-cyto CM induced changes in THP-1 gene expression as compared with control cell CM. Double conditioned medium (DCM) from the activated THP-1 cells was then applied to HMECs to determine whether paracrine signaling from PELP1-cyto-activated macrophages could in turn promote migration of HMECs. PELP1-cyto DCM induced robust HMEC migration, which was reduced in DCM from PELP1-cyto HMECs expressing IKKϵ shRNA. Our findings suggest that cytoplasmic localization of PELP1 up-regulates pro-tumorigenic IKKϵ and secreted inflammatory signals, which through paracrine macrophage activation regulates the migratory phenotype associated with breast cancer initiation.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  NF-kB transcription factor; breast cancer; cell migration; cell signaling; inflammation; macrophage

Mesh:

Substances:

Year:  2016        PMID: 27881676      PMCID: PMC5217692          DOI: 10.1074/jbc.M116.739847

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.

Authors:  Jodi E Goldberg; Kathryn L Schwertfeger
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

2.  Significance of PELP1 in ER-negative breast cancer metastasis.

Authors:  Sudipa Roy; Dimple Chakravarty; Valerie Cortez; Keya De Mukhopadhyay; Abhik Bandyopadhyay; Jung-Mo Ahn; Ganesh V Raj; Rajeshwar R Tekmal; LuZhe Sun; Ratna K Vadlamudi
Journal:  Mol Cancer Res       Date:  2011-11-15       Impact factor: 5.852

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Authors:  Valerie Cortez; Cathy Samayoa; Andrea Zamora; Lizatte Martinez; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

5.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.

Authors:  Jessica E Hutti; Rhine R Shen; Derek W Abbott; Alicia Y Zhou; Kam M Sprott; John M Asara; William C Hahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

6.  Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.

Authors:  Rajib Rajhans; Sujit Nair; Alan H Holden; Rakesh Kumar; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

7.  Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.

Authors:  Valerie Cortez; Monica Mann; Seshidhar Tekmal; Takayoshi Suzuki; Naoki Miyata; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2012-07-19       Impact factor: 6.466

8.  Targeting HER2(+) breast cancer: the TBK1/IKKε axis.

Authors:  Zhe Jiang; Jeff C Liu; Philip E D Chung; Sean E Egan; Eldad Zacksenhaus
Journal:  Oncoscience       Date:  2014-03-06

Review 9.  The evolution of the cancer niche during multistage carcinogenesis.

Authors:  Mary Helen Barcellos-Hoff; David Lyden; Timothy C Wang
Journal:  Nat Rev Cancer       Date:  2013-06-13       Impact factor: 69.800

10.  Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Authors:  S S Roy; V K Gonugunta; A Bandyopadhyay; M K Rao; G J Goodall; L-Z Sun; R R Tekmal; R K Vadlamudi
Journal:  Oncogene       Date:  2013-08-26       Impact factor: 9.867

View more
  5 in total

1.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

2.  Role of estrogen receptor coregulators in endocrine resistant breast cancer.

Authors:  Kristin A Altwegg; Ratna K Vadlamudi
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30

3.  Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes.

Authors:  Thu H Truong; Hsiangyu Hu; Nuri A Temiz; Kyla M Hagen; Brian J Girard; Nicholas J Brady; Kathryn L Schwertfeger; Carol A Lange; Julie H Ostrander
Journal:  Mol Cancer Res       Date:  2018-01-18       Impact factor: 5.852

4.  Cromolyn platform suppresses fibrosis and inflammation, promotes microglial phagocytosis and neurite outgrowth.

Authors:  Yi-Jun Wang; Matthew A Downey; Sungwoon Choi; Timothy M Shoup; David R Elmaleh
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

5.  PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.

Authors:  Carol A Lange; Julie H Ostrander; Thu H Truong; Elizabeth A Benner; Kyla M Hagen; Nuri A Temiz; Carlos Perez Kerkvliet; Ying Wang; Emilio Cortes-Sanchez; Chieh-Hsiang Yang; Marygrace C Trousdell; Thomas Pengo; Katrin P Guillen; Bryan E Welm; Camila O Dos Santos; Sucheta Telang
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 8.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.